SCHEMBL14015403

SCHEMBL14015403

Nc1ccc2ccn(Cc3ccc(Cl)c(Cl)c3)c(=O)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.42
▸ KDM4E B2RXH2 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ HPGD P15428 2/20 0.42
▸ S1PR2 O95136 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ UBE2N P61088 1/20 0.42
▸ KDR P35968 1/20 0.41
▸ DBH P09172 1/20 0.41
▸ HTR6 P50406 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ PRKACA P17612 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14015402 0.80 CCR2 (0.51) CCR2TDP1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2118972 0.78 HDAC6 (0.51) KDM4EALDH1A1
SCHEMBL2315711 0.77 SCD (0.63) SMN1; SMN2MAPK1LMNAHTTUBE2N
SCHEMBL5316206 0.76 SCD (0.46) TDP1SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL14138604 0.75 KDM4E (0.53) CCR2TDP1SMN1; SMN2KDM4EALDH1A1
SCHEMBL2312640 0.74 SCD (0.63) SMN1; SMN2MAPK1LMNAHTTUBE2N
SCHEMBL5697046 0.74 SIRT2 (0.39) SMN1; SMN2MAPTLMNA
SCHEMBL3843880 0.71 SCD (0.64) TDP1SMN1; SMN2MAPK1LMNAHTT
SCHEMBL2314577 0.70 SMN1; SMN2 (0.80) CCR2SMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL3423730 0.69 HDAC6 (0.62) KDRDBHHSP90B1TRAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255161-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS GILEAD PALO ALTO, INC. 2008-10-16 — — US disclosed
US-20080255161-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS GILEAD PALO ALTO, INC. 2008-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255161-A1 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS SCD, SCD5, ECHS1 CCR2 2508/4885TDP1 3084/4885SMN1; SMN2 3593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback